Natco Pharma submits application with USFDA for generic cancer drug

The company has submitted an Abbreviated New Drug Application (ANDA) containing a 'paragraph IV' certification with the US Food and Drug Administration (FDA) for the product, a generic version of AstraZeneca's Olaparib tablets in strengths of 100mg and 150mg.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/82vLirD
via IFTTT